Express yourself: Quantitative real-time PCR assays for rapid chromosomal antimicrobial

resistance detection in *Pseudomonas aeruginosa*

Danielle E. Madden[1,2], Olusola Olagoke[1,2], Timothy Baird[2,3], Jane Neill[2,3], Kay A. Ramsay[4], Tamieka A.

Fraser[1,2], Scott C. Bell[4,5,6], Derek S. Sarovich[1,2*], and Erin P. Price[1,2*]

[1]Centre for Bioinnovation, University of the Sunshine Coast, Sippy Downs, Queensland, Australia

[2]Sunshine Coast Health Institute, Birtinya, Queensland, Australia

[3]Respiratory Department, Sunshine Coast University Hospital, Birtinya, Queensland, Australia

[4]Child Health Research Centre, The University of Queensland, South Brisbane, Queensland, Australia

[5]Adult Cystic Fibrosis Centre, The Prince Charles Hospital, Chermside, Queensland, Australia

[6]Translational Research Institute, Woolloongabba, Queensland, Australia

Keywords: Antibiotic, AMR, gene expression, *Pseudomonas aeruginosa*, efflux pumps, qPCR, *ampC*,

genomics

Running title: Assays for rapid AMR detection in *P. aeruginosa*

*These authors contributed equally

Corresponding authors:

Derek Sarovich, dsarovich@usc.edu.au Ph: +61 7 5456 3748

Erin Price, eprice@usc.edu.au Ph: +61 7 5456 5568

Abstract

The rise of antimicrobial-resistant (AMR) bacteria is a global health emergency. One critical facet in

tackling this epidemic is more rapid AMR diagnosis in serious multi-drug resistant pathogens like

Pseudomonas aeruginosa. Here, we designed and then validated two multiplex quantitative real-

time PCR (qPCR) assays to simultaneously detect differential expression of the resistance-

nodulation-division efflux pumps MexAB-OprM, MexCD-OprJ, MexEF-OprN, MexXY-OprM, the AmpC

β-lactamase, and the porin OprD, which are commonly associated with chromosomally-encoded

AMR. Next, qPCRs were tested on 15 sputa from 11 participants with *P. aeruginosa* respiratory

infections to determine AMR profiles *in vivo*. We confirm multiplex qPCR testing feasibility directly

on sputa, representing a key advancement in *in vivo* AMR diagnosis. Notably, comparison of sputa

with their derived isolates grown in Luria-Bertani broth (±2.5% NaCl) or a 5-antibiotic cocktail

showed marked expression differences, illustrating the difficulty in replicating *in vivo* expression

profiles *in vitro*. Cystic fibrosis sputa showed significantly reduced *mexE* and *mexY* expression when

compared with chronic obstructive pulmonary disease sputa, despite harbouring fluoroquinolone-

and aminoglycoside-resistant strains, indicating that these loci are not contributing to AMR *in vivo.*

Sputum *ampC* expression was highest in participants receiving carbapenems (6.7-15x), some of

whom were simultaneously receiving cephalosporins, the latter of which would be rendered

ineffective by the upregulated *ampC*. Our qPCR assays provide valuable insights into the *P.*

aeruginosa resistome, and their use on clinical specimens will permit timely treatment alterations

that will improve patient outcomes and antimicrobial stewardship measures.

Introduction

The persistent rise in the prevalence and dissemination of antimicrobial-resistant (AMR) bacteria threatens to push humankind towards a post-antibiotic world (1) where untreatable superbugs endanger global health and food security and cause significant morbidity, mortality and economic burden (2). The opportunistic Gram-negative bacterium, *Pseudomonas aeruginosa*, is a member of the 'ESKAPE' group of AMR pathogens that represent the greatest concern to global health (3). *P. aeruginosa* can cause life-threatening infections (4), including in those with chronic respiratory diseases where localised immune defences are compromised such as cystic fibrosis (CF) or chronic obstructive pulmonary disease (COPD) (5). Once infection is established, *P. aeruginosa* eradication is made more difficult by many factors, including its high intrinsic AMR and its capacity to develop multi-drug resistance (MDR) to all classes of clinically-relevant antibiotics (6).

AMR diagnostics are a critical weapon in our battle against superbugs as they enable rapid, cost-effective, and high-throughput AMR detection, leading to more judicious and targeted antibiotic use (7). However, a lack of such diagnostics means that broad-spectrum antimicrobials are commonly used in the clinic in lieu of personalised treatments guided by antimicrobial sensitivity, genotype, and gene expression data (8). This practice, exacerbated during the COVID-19 pandemic (9), has unfortunately contributed to the emergence, persistence, and spread of AMR and MDR pathogens worldwide, with potentially devastating outcomes including treatment failure and mortality (10). Advancements in next-generation sequencing (NGS) technologies are enabling close-to-real-time identification of AMR (11). However, it is currently impractical and costly to use these technologies for rapid, high-throughput detection (12); as such, their implementation in routine clinical diagnostics is not yet feasible. Instead, nucleic acid-based detection platforms such as real-time PCR remain vital – and substantially cheaper, simpler, and more accessible in routine clinical microbiology services than NGS – for the rapid identification of pathogens and their AMR determinants (12). In addition to identifying AMR-conferring single-nucleotide polymorphisms

[SNPs] (13, 14), insertions/deletions (15), copy-number variants (16), gene gain (17, 18), or gene loss

(19), targeting altered RNA expression of key AMR loci (20-23) provides a rapid way to identify the

phenotypic consequences of the myriad genotypic variants that underpin AMR. For example, a

quantitative real-time PCR (qPCR) targeting upregulation of three key AMR resistance-nodulation-

division (RND) efflux pumps in the melioidosis pathogen, *Burkholderia pseudomallei*, enables the

simultaneous identification of meropenem (MEM) resistance, and decreased susceptibility towards

doxycycline and co-trimoxazole, in a single reaction (24).

Due to the large number of genetic mutations that can confer AMR in *P. aeruginosa* (25, 26), it

remains impractical to target each individual variant using PCR. Fortunately, most clinically-relevant

AMR in *P. aeruginosa* is thought to be conferred by a handful of key mechanisms, some of which

alter gene expression to drive the AMR phenotype (25). The primary AMR-conferring mutations in *P.*

aeruginosa include those that cause: i) *oprD* inactivation or repression, which commonly leads to

carbapenem resistance (27, 28); ii) *ampC* hyper-production, a predominant cause of β-lactam AMR

(25); iii) DNA gyrase A (*gyrA*) alteration, associated with fluoroquinolone (FQ) AMR (13, 29); and iv)

upregulation of one or more RND efflux pumps, leading to AMR or MDR (23). The most important

AMR-conferring RND efflux pumps in *P. aeruginosa* are MexAB-OprM (30) (FQs, β-lactams including

carbapenems (31), and β-lactam inhibitors (25)), MexEF-OprN (FQs) (32), MexXY (33)

(aminoglycosides and FQs (34)), and MexCD-OprJ (35) (FQs (36) and some fourth-generation

cephalosporins (37)).

Whilst PCR assays exist to individually detect differential gene expression of *ampC* (20, 26, 34), *mexB*

(22, 38), *mexX* (20, 39), *mexY, mexD, mexF* (22, 23), *mexA* and *oprD* (22, 34, 39) in *P. aeruginosa*,

none simultaneously detect expression of these genes. In addition, nearly all *P. aeruginosa* AMR

gene expression studies to date have assessed lab-cultured isolates (23, 38); with only one published

study assessing AMR gene expression *in vivo*, whereby singleplex assays were used to detect *ampC*

and *mexX* expression in 31 CF sputa, followed by comparison with corresponding derived isolates

(20).

To address these knowledge gaps, we developed and validated two multiplex qPCR assays to

simultaneously detect altered expression of six key genes that confer AMR towards most clinically-

relevant antibiotic classes, using *rpsL* as an internal reference gene for expression normalisation.

qPCRs were initially tested in cultures, and subsequently directly on 15 sputa, to permit *in vivo P.*

aeruginosa gene expression characterisation (20), thus removing transcriptional biases introduced

by culturing. qPCR results were also correlated with current anti-pseudomonal treatment to

determine the impact of antibiotic therapy on *in vivo* AMR gene expression, along with strain

phenotype and predicted *in silico* AMR genotype data.

Methods

Ethics statement and participant recruitment. This study was approved by The Prince Charles

Hospital (TPCH) Human Research Ethics Committee, project IDs HREC/13/QPCH/127 (CF) and

HREC/2019/QPCH/48013 (COPD). Site-specific approvals were obtained for CF recruitment at TPCH,

Brisbane, Australia, and COPD recruitment at Sunshine Coast Hospital and Health Service, Sunshine

Coast, Australia. CF sputa were collected from participants with chronic *P. aeruginosa* infection who

were admitted to the Cystic Fibrosis Centre at TPCH for intravenous antibiotic therapy; COPD sputa

was collected from participants either admitted to Sunshine Coast University Hospital (SCUH) for

pulmonary exacerbations, or whose symptoms were being managed at home as part of the

Respiratory Acute Discharge Service program; whether they had acute or chronic *P. aeruginosa*

infection was not known. All participants provided written consent.

Total RNA extraction and microbial RNA enrichment from sputa. Nine sputa from five CF

participants, and six sputa from six COPD participants (40) (Table 1), all with high-load *P. aeruginosa*

infections according to sputum culture onto MacConkey agar (Oxoid, Heidelberg West, VIC,

Australia), were subjected to total RNA extraction to determine *in vivo P. aeruginosa* AMR gene

expression profiles. Sputa were collected directly into RNA stabilisation reagent (10mM EDTA, 25mM

sodium citrate, 700g/L ammonium sulphate; pH=5.2; Sigma-Aldrich, Castle Hill, NSW, Australia) to

immediately halt transcriptional activity, and kept at 4∘C until RNA extraction (up to ~1 month).

Between 30 µL and 1 mL sputum was placed into 0.5-6 mL TRI Reagent LS (Sigma) and 30-240 µL 2-

mercaptoethanol (Sigma) aliquoted into sterile, RNase-free 2 mL O-ring tubes (SSIBio, Lodi, CA, USA)

containing ~100 µL equal mixture of 0.1 and 0.5 mm zirconia beads (Daintree Scientific, St Helens,

Tasmania, Australia). Tubes were parafilmed and subjected to four rounds of bead beating at 30 sec

pulses using the Minilys tissue homogeniser on the medium setting (Bertin Instruments, Montigny-

le-Bretonneux, France), with samples cooled on ice for >30 sec after each round to minimise RNA

degradation. Extracted RNA was treated with DNase Max (Qiagen), confirmed DNA-free using a 16S

ribosomal RNA gene PCR (41), and host RNA-depleted using MICROBEnrich (Thermo Fisher Scientific,

Seventeen Mile Rocks, QLD, Australia) as per manufacturer's instructions. cDNA (iScript; Bio-Rad,

Gladesville, NSW, Australia) was qPCR-tested at neat and 1:10 concentrations.

Growth conditions and antibiotic sensitivity testing. Nineteen *P. aeruginosa* strains (12 CF, 7 COPD)

were isolated from sputa using MacConkey agar and incubated at 37◦C for 24 h. Subcultures were

grown on Luria-Bertani (LB) agar (Oxoid) under the same conditions. All strains were confirmed as *P.*

aeruginosa by rapid chelex-100 (Bio-Rad) heat soak extraction (42) followed by *ecfX* real-time PCR

on a 1:50 dilution of the chelex supernatant (43). Susceptibility towards amikacin (AMK; 30µg),

cefepime (30µg), ceftazidime (CAZ; 30µg), ciprofloxacin (5µg), colistin (10µg), imipenem (10µg),

piperacillin (30µg), piperacillin-tazobactam (100µg/10µg), polymyxin B (300U), and tobramycin (TOB;

10µg) were determined by disc diffusion (Edwards Group, Murrarie, QLD, Australia); Etests were

used for MEM susceptibility testing (bioMérieux, Baulkham Hills, NSW, Australia). Sensitivity,

intermediate resistance, and AMR were determined using CLSI M100S-Ed27:2021 guidelines (Table

1). PAO1 (LMG 12228) was included as a wild-type reference. MDR was defined as non-susceptibility

to at least one antibiotic in three or more antibiotic classes (44).

Growth experiments and RNA extraction. To assess AMR gene expression levels in derived cultures,

a starting inoculum of 10^5 cells was grown to late-log phase (OD$_{600}$≈1) with orbital shaking at 250 rpm

(Ratek Laboratory Equipment [model number OM11], Boronia, VIC, Australia) for 16 h at 37◦C in 2mL

LB broth ±2.5% NaCl. RNA was extracted using TRI Reagent (Sigma-Aldrich) and treated with TURBO

DNase (Thermo Fisher Scientific) according to manufacturer's instructions. 1:10-diluted DNA-free

RNA was converted to cDNA using iScript. cDNA was diluted 1:25 in molecular-grade H$_2$O prior to

qPCR.

We also attempted to induce AMR gene expression in two *P. aeruginosa* cultures, SCHI0002.S.9 and

SCHI0010.S.1, using sub-inhibitory concentrations (0.25µg/mL each) of five antibiotics not used in *P.*

aeruginosa treatment but known to induce its RND efflux pumps – gentamicin for *mexX* upregulation

(45), novobiocin for *mexB* upregulation (31), norfloxacin for *mexC* upregulation (46),

chloramphenicol for *mexE* upregulation (47) and ampicillin for *ampC* upregulation (48). These strains

were selected as both encode MDR phenotypes; in addition, SCHI0010.S.1 encodes a high-

consequence frameshift mutation in MutS (R360fs), resulting in a hypermutator phenotype (49).

Multiplex AMR locus qPCR assay design and PCR conditions. To quantify *mexAB-oprM*, *mexCD-oprJ*,

mexEF-OprN, *mexXY-OprM*, *ampC*, and *oprD* expression, two multiplex assays targeting the *mexB,*

mexC, mexE, *mexY*, *ampC*, and *oprD* genes, respectively, were designed (Table 2). A BLAST database

comprising 730 *P. aeruginosa* genomes (50-54) was used to identify conserved regions for oligo

design. Oligo self-dimers and heterodimers were assessed and avoided as previously described (55).

Each PCR consisted of 1× SsoAdvanced Universal Probes Supermix (Bio-Rad), optimised primer and

probe concentrations (Macrogen Inc., Geumcheon-gu, Seoul, South Korea; Table 2), 1 µL genomic

DNA (gDNA) or cDNA template, and PCR-grade H_2O, to 5 µL. Isolate gDNA/cDNA thermocycling

comprised enzyme activation at 95∘C for 2 min, followed by a 2-step program (95∘C for 5 sec and

60∘C for 15 sec) for 45 cycles; for sputum cDNA, a 3-step program (95∘C for 5 sec, 60∘C for 15 sec,

and 72∘C for 15 sec) for 45 cycles was used to enhance *P. aeruginosa* detection from polymicrobial

DNA.

qPCR assay limits of detection (LoD) and quantification (LoQ). LoD and LoQ values were determined

for each assay when in multiplex format using 1:10 serial dilutions of SCHI0005.S.10 *P. aeruginosa*

genomic DNA ranging from 40 to 4×10^{-6}ng across eight replicates, as previously described (56, 57).

Genome equivalents (GEs) were calculated based on the average PAO1 genome size of 6.22Mbp and

a single copy of each gene. For all assays, all samples were run in duplicate, and at least two no-

template controls were included in each run.

qPCR normalisation and analysis. The constitutively expressed *rpsL* gene was used to normalise

AMR gene expression via the difference in cycles-to-threshold (ΔC_T) method (34, 58). After *rpsL*

normalisation, ΔC_T values were further normalised against either PAO1 expression, or to

SCHI0070_D2 COPD sputum ($\Delta\Delta C_T$), the latter of which enabled gene expression comparison among

sputa, and between sputa and derived isolates. SCHI0070_D2 COPD sputum was chosen for

normalisation as this participant had no recent history of anti-pseudomonal antibiotic treatment, its

derived isolate, SCHI0070.S.1, was sensitive towards all 11 anti-pseudomonal antibiotics (Table 1),

and there was good gene expression across all seven loci for this sample. For AMR loci lacking

detectable PCR amplification, a C_T value of 45 was assigned to permit visualisation of genes with very

low/no expression. According to previously defined criteria (23), strains were regarded as hyper-

producers if their AMR loci exhibited >10-fold higher expression compared with PAO1, except for

mexB and *mexY,* which were considered hyper-producing if >3-fold higher expression than PAO1 (23,

34, 38).

AMR prediction from genomes. *In silico* AMR prediction for 16 genome-sequenced isolates, plus

PAO1 (Table 1), was carried out using the *P. aeruginosa*-specific database in ARDaP v1.9 (59)

(available at: https://github.com/dsarov/ARDaP). The genomes of 14 strains have been previously

published (13); paired-end Illumina genomes for SCHI0065.S.1 and SCHI0070.S.1 were generated in

the current study and appended to NCBI BioProject PRJNA761496. We did not sequence

SCHI0018.S.11, SCHI0038.S.2, or SCHI0038.S.4 as these data were not considered essential for study

outcomes.

Statistical analysis. Gene expression differences were assessed using a two-way analysis of variance

test and Tukey's multiple comparison test using GraphPad Prism (GraphPad Software Inc., CA, USA).

Corrected *p* values of <0.05 were considered significant.

Results

Multiplex qPCR assay performance. To assess assay sensitivity, LoD and LoQ values were

determined using a 10-fold DNA dilution series (40 ng to 0.04 fg). The LoD for all assays was 400 fg

(59 GEs), the LoQ for *mexB, mexE* and *mexC* was 400fg (59 GEs), and the LoQ for *rpsL, ampC, mexY*

and *oprD* was 4000 fg (587 GEs) (Figures S1 and S2).

Antibiotic susceptibility profiles. Testing towards 11 anti-pseudomonal antibiotics identified much

higher rates of AMR (range: 0-9 antibiotics) and MDR (10/12 strains) in CF-derived isolates when

compared with COPD-derived isolates (range: 0-2 antibiotics; 0/7 MDR strains) (Table 1). This was

consistent with much greater antibiotic use in the CF cohort (Table 1) (40). The lowest susceptibility

rates were towards cefepime (0% CF and 100% COPD) and piperacillin (33% CF and 100% COPD),

whereas all 19 strains were susceptible to colistin and polymyxin B (Table 1). Interestingly, cefepime

is rarely used for CF treatment at TPCH, indicating probable cross-resistance towards this antibiotic

in all CF-derived isolates. None of the participants were receiving polymyxins; as such, no AMR was

expected towards these antibiotics.

***In silico* AMR prediction.** Genomic analysis of the derived *P. aeruginosa* isolates revealed a much

greater number of AMR determinants in the CF-derived strains (Table 1). Although some AMR

determinants were identified in COPD isolates, none were associated with dysregulated expression

of the six AMR loci. In contrast, many CF-derived isolates encoded mutations predicted to alter gene

expression of our qPCR gene targets (Table 1). Specifically, *ampC* overexpression was predicted in

SCHI0030.S.2 and SCHI0030.S.3 due to AmpD regulator loss (P42fs) (60); *mexAB-oprM*

overexpression was predicted in SCHI0002.S.9 and SCHI0002.S.12 due to a D187H missense

mutation in the NalD regulator (61); and *mexCD-oprJ* overexpression was predicted in SCHI0030.S.4

due to NfxB regulator loss (F126fs) (62). No mutations associated with *mexEF-oprN* or *mexXY-oprM*

overexpression were identified. Although not associated with gene expression changes, *oprD* loss

was predicted in SCHI0002.S.8 (W339Ter) and SCHI0030.S.3 (G193fs), which is linked to carbapenem

resistance, especially when associated with *ampC* upregulation (25, 63) as observed in SCHI0030.S.3.

Other AMR determinants were identified in our strain dataset, including multiple determinants

encoding decreased susceptibility or AMR towards CIP (GyrA T83I, D87H or D87N, GyrB S466F and

ParE A473V (64)) (Table 1). In addition, an R504C missense variant in FtsI, known to confer resistance

to β-lactams (65), was detected in three CF-derived, multi-β-lactam-resistant isolates (SCHI0002.S.8,

SCHI0030.S.2, and SCHI0030.S.3), and a FusA1 missense mutation, A555E (66), was identified in CF-

derived isolate SCHI0010.S.1 (AMK- and TOB-resistant) (Table 1). Finally, MexEF-OprN loss was

predicted in SCHI0013.S.2 and SCHI0013.S.12 due to a frameshift (R229fs) in the MexE membrane

fusion protein, and in SCHI0030.S.2 and SCHI0030.S.3 due to the introduction of a stop codon

(Y37Ter) in the MexF multidrug inner membrane transporter (67). Unlike the AMR variants, these

mexE and *mexF* mutations render the MexEF-OprN pump inoperable, and thus unable to contribute

towards AMR, irrespective of *mexEF-oprN* upregulation.

Comparison of AMR variant prediction with *in vitro* AMR gene expression. Relative AMR gene

expression in derived *P. isolates* grown in LB broth (*n*=15; Figure S3), LB+NaCl (*n*=14; Figure S4), or a

5-antibiotic cocktail (*n*=2; Figure S5) was assessed. All qPCR targets exhibited expression in at least

one strain; however, in some strains, particularly the CF-derived isolates, certain genes exhibited no

expression (Figures S3-S5). Just two loci were expressed in all tested strains across all conditions: the

housekeeping gene *rpsL* (C_T=25.3±1.97) and *mexB* (C_T=29.0±2.14). *oprD* was expressed in all strains

except SCHI0039.S.1 grown in LB+NaCl. In contrast, *ampC*, and *mexC*, *mexE*, and *mexY* were

expressed in 1, 23, 26, and 2 of the 31 tested strains, respectively. Genetic analysis of all qPCR-

targeted loci confirmed 100% primer and probe matches in those strains with genomic data, thereby

ruling out assay failure as a cause of undetectable expression.

Unexpectedly, there was no concordance between *in silico* AMR predictions and qPCR results for

strains grown under any of the tested conditions. SCHI0030.S.2 and SCHI0030.S.3, which were

predicted to upregulate *ampC* through a previously undocumented AmpD frameshift variant (P42fs),

exhibited negligible or no *ampC* expression when grown in LB broth or LB+NaCl (Figures S3 and S4).

In contrast, SCHI0010.S.1, which does not encode any known chromosomal variant associated with

ampC upregulation (Table 1), demonstrated *ampC* hyper-expression (43x) in LB broth relative to

PAO1, although no detectable *ampC* expression under salt (Figure S2) or antibiotic stress (Figure S3).

Similarly, SCHI0002.S.9 and SCHI0002.S.12 failed to overexpress *mexB*, and SCHI0030.S.4 failed to

overexpress *mexC*, despite predicted upregulation. Once again, SCHI0010.S.1 grown in LB, but not in

LB+NaCl, unexpectedly hyper-expressed *mexB* (19x), *mexC* (19x), *mexE* (24x), and *mexY* (16x) in lieu

of encoding any known variants associated with upregulation of these loci. No other strain tested

under any condition upregulated *mexB*, *mexC*, *mexE*, or *mexY*. Although no strains were predicted to

exhibit *oprD* downregulation, *oprD* was not expressed in SCHI0039.S.1 grown in LB±NaCl, and was

significantly downregulated in SCHI0010.S.1 grown in LB+NaCl (Figures S3 and S4). All other strains

exhibited good *oprD* expression, including SCHI0002.S.8 and SCHI0030.S.3; although these strains

encode truncated OprD, these deleterious mutations occur downstream of the oligo-binding sites,

and are therefore undetected by our assay.

AMR gene expression in sputa. All COPD sputa yielded more similar expression profiles to the

SCHI0070_D2 COPD control than any of the nine CF sputa (Figure 1). The only overexpressed loci in

the CF or COPD sputa were: *ampC* (4/9 CF [1.7-15.1x] and 2/5 COPD [1.7-3.5x]), *mexB* (3/5 COPD

[1.5-2.5x]), *mexC* (2/9 CF [1.7-2.1x] and 2/5 COPD [6.4x each]), *mexY* (4/5 COPD [1.8-7.3x]), and *oprD*

(3/5 COPD [1.7-51x]) (Figure 2). All CF sputa exhibited downregulation or no expression of *mexB*

(≥4.0x), *mexE* (≥3.9x), *mexY* (≥5.2x), and *oprD* (≥377x), and 6/9 were downregulated or had no

detectable expression for *mexC* (≥3.4x). When comparing CF and COPD sputum expression, no

significant difference was observed for *ampC*, *mexB*, *mexC*, or *oprD*; in contrast, *mexE* and *mexY*

were all significantly downregulated in CF sputa (Figure 1).

Correlation of qPCR results with antibiotic treatment (Table 1) identified that sputum *ampC*

expression levels were a good indicator of current β-lactam use, with 4/5 sputa with elevated *ampC*

expression collected from participants contemporaneously receiving β-lactams (SCHI0002_D8,

SCHI0010_D7, SCHI0013_D4, and SCHI0018_D8). Notably, 2/3 sputa (SCHI0002_D8 and

SCHI0013_D4) obtained from participants being treated with MEM, either with or without CAZ,

overexpressed *ampC* at high levels (6.7-15x); in contrast, *ampC* expression was only moderately

upregulated (1.7-1.9x) in two sputa (SCHI0010_D7 and SCHI0018_D8) from participants on CAZ but

not MEM (Table 1; Figure 2). *ampC* was downregulated or not expressed in eight sputa (Figure 2) - of

these, four were collected from participants receiving no antibiotics at the time of collection, three

were receiving antibiotics other than β-lactams, and just one (SCHI0002_D329) was receiving CAZ

and MEM at the time of sputum collection (Table 1).

AMR gene expression between sputa and *in vitro* cultures. Sputum AMR gene expression was

compared with derived cultures grown in LB broth (Figure S3), LB+NaCl (Figure S4), and a 5-antibiotic

cocktail (Figure S5) to determine whether culture AMR gene expression was reflective of *in vivo*

conditions. Overall, there was very poor concordance between *in vivo* and *in vitro* expression

profiles across all tested *in vitro* conditions, with most loci exhibiting dissimilar expression between

derived isolates and their corresponding sputa. Most striking was *oprD*, which, in most cases, was

upregulated in strains grown under the three *in vitro* conditions (Figures S3-S5) yet largely

downregulated *in vivo* (Figure 2).

RND efflux pump expression during antibiotic treatment. The four longitudinal sputa collected from

SCHI0030, who received intravenous TOB and aztreonam for 15 days, provides an interesting case

study for observing AMR gene expression dynamics before, during, and after antibiotic treatment

(Table 1). Although TOB has previously been shown to induce MexXY-OprM expression in CF sputa

(20), we unexpectedly did not observe AMR gene expression changes in SCHI0030 sputa (Figure 2).

Five sputa from other CF participants also showed limited or no *mexY* expression. In comparison,

mexY was significantly upregulated in 4/5 COPD sputa (Figure 2), none of whom have ever received

TOB (Table 1).

Discussion

Here, we developed and validated two multiplex qPCR assays for the simultaneous detection of

altered AMR locus expression in the ESKAPE pathogen, *P. aeruginosa*. When run in multiplex format,

our qPCRs showed very good to excellent LoD and LoQ values. qPCRs can be used both on *P.*

aeruginosa cultures and directly on human RNA-depleted sputa, the latter of which provides *in vivo*

expression profiling that overcomes transcriptional bias introduced with *in vitro* culture (20).

Building upon the pioneering work of Martin and colleagues, who first reported limited correlation

in *ampC* and *mexX* expression between sputa and corresponding derived isolates (20), we also

observed poor concordance between *in vivo* and *in vitro* expression profiles across six tested AMR

loci. Further, we found surprisingly poor correlation between *in silico*-predicted and *in vitro* AMR

gene expression. These findings raise questions about the clinical utility of *in vitro* antimicrobial gene

expression profiling and highlight the need for more work in this critical area of AMR research.

AmpC-driven AMR. We found that sputum *ampC* expression correlated well with contemporaneous

β-lactam treatment. In particular, two CF participants (SCHI0010 and SCHI0018) receiving CAZ but no

other β-lactams overexpressed *ampC* at moderate levels (1.7-2x); this overexpression increased to

6.7-15x in two other participants (SCHI0002 and SCHI0013) receiving MEM (Table 1; Figure 2).

Carbapenems such as MEM can be potent *ampC* inducers (63) and can remain effective even when

ampC expression is elevated (25), whereas cephalosporins such as CAZ are relatively weak inducers

of *ampC* and are readily hydrolysed by this enzyme (25). Our findings confirm that MEM can act as a

strong inducer of *ampC* expression *in vivo*. In light of this, we recommend that *P. aeruginosa*

infections should not simultaneously be treated with carbapenems and cephalosporins due to

potential *ampC* induction, which would render cephalosporin (and likely other β-lactam) antibiotics

ineffective (25). In contrast, eight sputa exhibited downregulated or no *ampC* expression (Figure 2),

seven of which were taken from participants either not on antibiotics or not receiving β-lactams at

the time of sample collection, which likely explains the lack of β-lactam-driven *ampC* selection

pressure. Of note, two COPD sputa, SCHI0109 and SCHI0050_D3, showed *ampC* upregulation (1.7-

3.5x), despite neither participant receiving contemporaneous β-lactam therapy. Whilst the basis for

this upregulation is unknown, we speculate that β-lactam use in these participants would be

ineffective for *P. aeruginosa* eradication. Taken together, our results demonstrate that routine *ampC*

qPCR testing of *P. aeruginosa*-positive specimens is a useful diagnostic for monitoring *in vivo*

cephalosporin efficacy, enabling more rapid treatment shifts in instances where *ampC* is

upregulated.

Unlike sputa, almost all derived isolates failed to express *ampC* when grown in three different liquid

media. The exception was the derived isolate from CF participant SCHI0010. In LB broth,

SCHI0010.S.1 exhibited *ampC* hyper-expression (15x relative to SCHI0070_D2, and 43x relative to

PAO1; Figure S3), yet the corresponding sputum showed only modest *ampC* upregulation (1.7x;

Figure 2). This finding was unexpected as SCHI0010.S.1 does not encode any known chromosomal

variant associated with *ampC* upregulation (Table 1), and did not overexpress *ampC* when grown in

LB+NaCl or the 5-antibiotic cocktail (Figures S4-S5). These results indicate that SCHI0010.S.1 encodes

an enigmatic determinant for upregulating *ampC* expression when grown under particular

conditions. Whilst the basis of this overexpression requires further investigation, we postulate that it

may be driven by global transcriptional regulator inactivation due to its hypermutator status,

resulting in marked transcriptome differences affecting multiple gene pathways. In contrast, strains

SCHI0030.S.2 and SCHI0030.S.3, both predicted to upregulate *ampC* due to a truncated AmpD,

exhibited negligible or no *ampC* expression *in vitro* (Figures S3-S4). This result correlated with all

longitudinal SCHI0030 sputa which exhibited significantly downregulated *ampC* expression. One

possibility for the lack of *ampC* expression in SCHI0030 is that the AmpD P42fs mutation may only

confer a partially de-repressed *ampC* phenotype (26); another possibility is that additional

chromosomal determinants, such as those occurring in other AmpD homologues (26) or DacB (68),

may be required to confer *ampC* upregulation (60) in AmpD P42fs-encoding strains.

Expression of *ampC* was also undetectable in the MDR strain, SCHI0002.S.9, across the three *in vitro*

conditions (Figures S3-S4). Whilst this observation is consistent with the lack of predicted *ampC*

dysregulation in the SCHI0002.S.9 genome, it does not reflect the AMR phenotype of this strain,

which was resistant to all six tested penicillin, cephalosporin, and carbapenem antibiotics (Table 1).

In addition, the corresponding SCHI0002_D8 sputum displayed the greatest *ampC* upregulation (15x;

Figure 2), probably due to contemporaneous CAZ and MEM treatment (Table 1). One possible

explanation for these spurious results is that high sputum *ampC* levels are conferred by an un-

retrieved *P. aeruginosa* strain (20), as supported by two distinct AMR phenotypes and genotypes

isolated from SCHI0002_D8, SCHI0013_D4, and SCHI0030_D50 sputa (Table 1). Indeed, phenotypic

and genotypic diversity of *P. aeruginosa* is well-documented in chronic CF infections (69), and

increasingly in COPD infections (70). Another explanation is that *ampC* expression in SCHI0002

strains may require MEM (20) or cefoxitin (71) rather than ampicillin (48) for *in vitro* induction, as

certain antibiotics are known to be better than others for inducing *ampC* (20). However, antibiotic

induction only provides a crude representation of *in vivo P. aeruginosa* activity, as the lung

environment is exceptionally difficult to mimic *in vitro* (20, 69, 72). The lack of correlation between

ampC upregulation in sputa and derived cultures (Figures S3-S5) has also been reported in a

separate study (20), and emphasises the challenges in replicating *in vivo* conditions *in vitro*.

Efflux-mediated AMR. *mexB*, *mexC*, *mexE* and *mexY* represent the RND efflux pumps most

frequently associated with AMR and MDR in *P. aeruginosa* (23, 25). As most CF participants were

being treated with anti-pseudomonal antibiotics at the time of sputum collection, and many of their

derived isolates encode key mutations associated with altered RND efflux pump expression (Table

1), we expected upregulation of these four efflux pumps in CF sputa. It was therefore surprising that

mexC was the only efflux system that demonstrated modest (1.7-2.1x) upregulation in a few patients

(2/9 CF sputa), whereas the other RND efflux systems were largely downregulated, or switched off

entirely, in CF sputa (Figure 2). Also surprising was that most COPD sputa showed good expression of

these loci, despite only two COPD participants contemporaneously receiving anti-pseudomonal

antibiotics, and almost no AMR phenotypes or efflux pump expression-altering genotypes in the

derived COPD isolates (Table 1). This difference between diseases was most apparent for *mexE* and

mexY, which were significantly downregulated in CF but not COPD sputa (Figure 1). Although our

dataset is small, these observations suggest that RND efflux pump expression, and particularly *mexE*

and *mexY* expression, may not be required for chronic *P. aeruginosa* persistence in CF airways. This

finding contradicts prior *in vitro* work suggesting that MexXY-OprM efflux pump upregulation is

necessary for *P. aeruginosa* survival in the CF lung (73). We further postulate that the MexEF-OprN

and MexXY-OprM RND efflux pumps may have a minimal role, if any, in conferring AMR in *P.*

aeruginosa in vivo. *mexE* and *mexY* qPCR testing across a larger CF and COPD sputum panel is

needed to determine to veracity of our findings.

One possible explanation for efflux pump downregulation in CF sputa is that the CF cohort all

harboured chronic *P. aeruginosa* infections, whereas the COPD cohort potentially only had transient

(i.e. acute) infections. Like virulence factors (74), RND efflux pump expression may be upregulated

during the acute phase but then downregulated once *P. aeruginosa* transitions to a chronic lifestyle,

the latter of which is characterised by biofilm formation and reduced metabolic activity (25, 75). In

support of this hypothesis, longitudinal sputa collected from CF participant SCHI0030 just prior,

during, and after a 15-day course of intravenous TOB and aztreonam treatment showed virtually no

change in RND efflux pump expression, with all AMR genes (including *mexY*) downregulated (Figure

2) despite the aminoglycoside onslaught. In addition, one of two SCHI0030 strains obtained 35 days

after antibiotic cessation was fully susceptible to all 11 tested antibiotics, including TOB, hinting at

insufficient antibiotic penetration due to biofilm. As ours is one of the few studies to investigate *P.*

aeruginosa AMR gene expression *in vivo*, and the first to assess COPD sputa, more work is required

to verify these hypotheses, as there remains stark limitations in our understanding of the

characteristics of *P. aeruginosa* infection (including AMR development), particularly in people with

COPD (76). Examining *in vivo* AMR gene expression dynamics over a long-term *P. aeruginosa*

infection would shed important information about the adaptive processes that occur during the

transition from acute infection to chronic persistence. We anticipate that our multiplex assays will

be a valuable tool for such studies.

Analysis of RND efflux expression among the CF-derived isolates encoding predicted RND efflux

upregulation revealed that almost none demonstrated increased efflux pump expression *in vitro*

(Figures S3-S5). Curiously, the MDR and hypermutated isolate SCHI0010.S.1, which does not encode

any known mutations associated with RND efflux pump upregulation, exhibited *mexB* (5.3x), *mexC*

(1.7x), *mexE* (1.5x), and *mexY* (28x) overexpression when grown in LB, although not when grown in

LB+NaCl or the 5-antibiotic cocktail (Figures S3-S5). These results indicate that there are growth-

specific requirements associated with upregulation of these genes. Furthermore, these observations

collectively indicate that *in vitro* efflux pump expression is not a good proxy for AMR phenotype, as

our CF-derived *P. aeruginosa* isolates demonstrate extensive MDR, yet we were unable to reproduce

their expected gene expression alterations *in vitro*. Our results contradict other *in vitro* experiments

reporting RND efflux pump hyper-expression as a major contributing factor to AMR development in

CF airway-derived *P. aeruginosa* (34, 39). Caution should thus be taken when attempting to correlate

predicted AMR phenotypes with *in vitro* RND efflux pump expression profiles due to considerable

AMR gene expression changes exhibited under different culture conditions.

OprD-mediated AMR. As with the other AMR loci, we saw an unexpectedly poor correlation

between *in vitro* and *in vivo oprD* expression. Whereas 17/19 *in vitro* cultures expressed *oprD* at high

levels (Figures S3-S5), 9/9 CF and 2/5 COPD sputa exhibited no detectable *oprD* expression (Figure

2). This finding strongly suggests that *oprD* downregulation is a common, and potentially dominant,

adaptive *in vivo* trait in chronic *P. aeruginosa* infections. Another noteworthy observation is that *in*

vivo oprD downregulation was not strictly associated with contemporaneous carbapenem use, as

only three of the CF sputa were obtained during carbapenem treatment, and none of the COPD

participants had ever received carbapenems. We posit that this adaptive mechanism may provide a

rapid, efficient, and effective way for *P. aeruginosa* to evade carbapenems in lieu of encoding

functional *oprD* loss. In support of this hypothesis, two prior studies reported decreased *oprD*

expression as a cause of carbapenem AMR in 19/33 (58%) (77) and 39/117 (33%) (78) clinical

isolates. However, another study showed that *in vitro oprD* downregulation in carbapenem-resistant

isolates is a rare event, occurring in just 5/40 (13%) isolates (34). As our study illustrates, the

markedly different *oprD* expression profiles observed among studies may reflect differing *in vitro*

growth conditions; nevertheless, these *in vitro* findings show that *P. aeruginosa* can modulate its

oprD expression to confer carbapenem AMR. Like *ampC*, our *oprD* results indicate that there may be

great clinical value in characterising *in vivo oprD* expression to rapidly identify *P. aeruginosa*

infections that are recalcitrant to carbapenem therapy.

Concluding remarks. Our results add further weight to growing concerns about the relevance of *in*

vitro AMR research, particularly *in vitro* gene expression analysis, in clinical practice (79, 80). Due to

poor correlation between *in vitro* AMR testing and treatment outcomes in CF, empirical antibiotic

selection remains the preferred option due to better patient responses (72). Our findings confirm

that alternative approaches must be explored that minimise the transcriptional biases introduced

during culture (81) to better reflect *in vivo P. aeruginosa* gene expression (79). We recommend that,

wherever possible, gene expression of clinical specimens (e.g. sputum) be tested alongside cultured

isolates (20). This information will greatly improve our understanding of the shortcomings of *in vitro*

AMR testing whilst aiding in clinical decision making, providing more targeted treatment strategies,

enhancing antimicrobial stewardship, and improving patient outcomes.

Acknowledgements

This work was supported by Advance Queensland (awards AQIRF0362018 and AQRF13016-17RD2),

an Australian Government Research Training Program Scholarship, the Wishlist Sunshine Coast

Health Foundation (award 2019-14), the IMPACT Philanthropy Application Program

(IPAP2016/01112), UQ-QIMRB (Australian Infectious Disease Grant initiative), the National Health

and Medical Research Council (award 455919), The Children's Health Foundation Queensland (50 0

07), and The Health Innovation, Investment and Research Office of Queensland Health. The funders

had no role in study design, data acquisition, analysis, interpretation, writing or submission of the

manuscript.

Tables

Table 1. *Pseudomonas aeruginosa*-positive sputa, corresponding derived isolates, and disc diffusion profiles across 11 anti-pseudomonal antibiotics

Disease	Sputum ID†	Derived isolate ID	Aminoglycosides		Penicillins		Cephalosporins		FQs	Polymyxins		Carbapenems		Treatment	AMR prediction from genomic data
			AMK	TOB	PIP	TZP	CAZ	FEP	CIP	CST	PMB	IPM	MEM#		
CF	SCHI0002 (Day 8)	SCHI0002.S.8	S	S	R	I	I	R	I	S	S	R	S	IV CAZ, MEM, TOB	GyrB S466F (CIPi); OprD W339Ter (MEMr, IPMr); FtsI R504C (MEMr, IPMr, CAZr; FEPr, TZPr, PIPr)
		SCHI0002.S.9	R	S	R	R	R	R	I	S	S	R	R	IV CAZ, MEM, TOB	NalD D187H (CIPi, FEPi, CAZi, MEMi, IPMi); PA3127 loss (PIPr)
	SCHI0002 (Day 329)	SCHI0002.S.12	R	R	R	R	R	R	I	S	S	S	S	IV CAZ, MEM, TOB	NalD D187H (CIPi, FEPi, CAZi, MEMi, IPMi); PA2326 loss (PIPr, FEPr); PA3127 loss (PIPr)
	SCHI0010 (Day 7)	SCHI0010.S.1	R	R	R	R	R	R	R	S	S	R	R	IV CAZ, TOB	FusA1 A555E (AMKr, TOBr); GyrA T83I (CIPr); PA2693 D17fs (PIPr, TZPr, MEMr, FEPr, CAZr); PA2531 A137fs (PIPr); PckA G418fs (PIPr); *aac(6')-IIa* (TOBr)
	SCHI0013 (Day 4)	SCHI0013.S.2	S	R	S	S	S	I	S	S	S	R	S	IV FOF, MEM	GyrB S466Y (CIPi), ParE A473V (CIPi), PA1942 loss (PIPr), MexE R229fs (CIPs); *ant(2'')-Ia* (TOBr)
		SCHI0013.S.12	R	S	R	S	S	R	I	S	S	R	I	IV FOF, MEM	GyrB S466Y (CIPi); ParE A473V (CIPi); MexE R229fs (CIPs)
	SCHI0018 (Day 8)	SCHI0018.S.11	S	R	R	I	R	I	S	S	S	S	---	IV CAZ, TZP, TOB	Not sequenced
	SCHI0030 (Day 0)	SCHI0030.S.1	S	S	S	S	S	I	S	S	S	S	S	Nil	None
	SCHI0030 (Day 6)	SCHI0030.S.2	R	R	R	R	R	R	I	S	S	R	R	IV ATM, TOB	PA1821 loss (PIPr, TZPr); MexF Y37Ter (CIPs); AmpD P42fs (CAZi, PIPi, TZPi, FEPi, IPMi, MEMi); FtsI R504C (MEMr, IPMr, CAZr, FEPr, TZPr, PIPr); GyrA D87H (CIPr)
	SCHI0030 (Day 13)	SCHI0030.S.3	R	I	R	R	R	R	R	S	S	R	R	IV ATM, TOB	AmpD P42fs (CAZi, PIPi, TZPi, FEPi, MEMi, IPMi); OprD G193fs (MEMr, IPMr); MexF

Group	Patient	Isolate												Antibiotics	Mutations
															Y37Ter (CIPs); FtsI R504C (MEMr, IPMr, CAZr, FEPr, TZPr, PIPr); GyrA D87H (CIPr)
	SCHI0030 (Day 50)*	SCHI0030.S.4	R	R	R	R	R	R	R	S	S	R	R	Nil	NfxB F126fs (CIPr, FEPr)
		SCHI0030.S.5	S	S	S	S	S	S	S	S	S	S	S	Nil	None
COPD	SCHI0038*	SCHI0038.S.2	I	R	S	S	S	S	S	S	S	S	S	Nil	Not sequenced
		SCHI0038.S.3	S	S	S	S	S	S	S	S	S	S	S	Nil	None
		SCHI0038.S.4	S	I	S	S	S	S	S	S	S	S	S	Nil	Not sequenced
	SCHI0039*	SCHI0039.S.1	S	S	S	S	S	S	S	S	S	S	S	Nil	PA0090 R532_E535delinsQ (TZPr, FEPr, PIPr)
	SCHI0050 (Day 3)	SCHI0050.S.1	S	S	S	S	S	S	S	S	S	S	S	Oral CIP	ParC Q405R (precursor; causes CIPr in combination with a *gyrA* mutation)
	SCHI0065*	SCHI0065.S.1	S	S	S	S	S	S	S	S	S	S	S	Oral AZM	None
	SCHI0070 (Day 2)*	SCHI0070.S.1	S	S	S	S	S	S	S	S	S	S	S	Oral AMC	None
	SCHI0109	Not retrieved	---	---	---	---	---	---	---	---	---	---	---	Oral CIP and AZM; azathioprine	---
Control	---	PAO1	S	S	S	S	S	S	S	S	S	S	S	---	None

Abbreviations: AMK, amikacin; AMR, antimicrobial resistance; ATM, aztreonam; AZM, azithromycin; CAZ, ceftazidime; cDNA, complementary DNA; CF,

cystic fibrosis; CIP, ciprofloxacin; CST, colistin; COPD, chronic obstructive pulmonary disease; FEP, cefepime; FOF, fosfomycin; FQ, fluoroquinolones; fs,

frameshift; I or i, intermediate resistance; IPM, imipenem; MEM, meropenem; PMB, polymyxin B; PIP, piperacillin; R or r, antimicrobial resistant; S or s,

antimicrobial sensitive; TZP, piperacillin/tazobactam; TOB, tobramycin; AZM, azithromycin; AMC, amoxicillin/clavulanic acid

†Days since commencing antibiotics

*Not receiving anti-pseudomonal antibiotics at time of sputum collection

#MEM antibiotic resistance profiles were determined using E-Tests

Table 2. Primers and probes designed in this study

Multiplex	Gene target	AMR target	Fluorophore	Oligo name	Oligo sequence (5'-3')	Optimised concentration (μM)
1	*mexY*	RND efflux pump	HEX	mexY-For	AAGAGGACCAGGGCGACTTC	0.20
				mexY-Rev	CTTCAGGGTGGCGAAGATCAT	0.20
				mexY-Probe	TGAAGCCGCCGACCGCA	0.20
	mexB	RND efflux pump	FAM	mexB-For	ACCGTGGTCCAGGTGATCG	0.15
				mexB-Rev	AGTTACTCTCCGAGGAGATGTAGCG	0.15
				mexB-Probe	CAGCAGATGAACGGGATCG	0.20
	ampC	β-lactamase	Texas Red	ampC-For	CTTCGACGGCATCAGCCT	0.45
				ampC-Rev	CCGATGCTCGGGTTGGA	0.45
				ampC-Probe	CAGATCCGCGACTACTACCGCCAGTG	0.20
	rpsL	Housekeeping gene	Cy5	rpsL-For	CGACAAGAGCGACGTGCC	0.25
				rpsL-Rev	TTACGCAGTGCCGAGTTCG	0.25
				rpsL-Probe	CATACGCCACGACGTTGCG	0.20
2	*mexC*	RND efflux pump	HEX	mexC-For	GTGCTGTTCGAGGCGCAG	0.20
				mexC-Rev	TCCTGCTGGCTGACCGC	0.20
				mexC-Probe	CTGGATCTTCACCAGCGGCT	0.25
	oprD	Porin	FAM	oprD-For	AAGTGGAGCGCCATTGCA	0.20
				oprD-Rev	TAGTAGTTGCGGAGCAGCAGGT	0.20
				oprD-Probe	CTGCTGTCTTCGATGAACC	0.20
	mexE	RND efflux pump	Texas Red	mexE-For	TACCTCGGCCTGAGCAGC	0.25
				mexE-Rev	GTTGACCTGGTTGTCGAGGAAG	0.25
				mexE-Probe	ACGGCAACCCGCACCTG	0.30

Abbreviations: AMR, antimicrobial resistant (allele); cDNA, complementary DNA; RND, resistance-nodulation-division; SNP, single-nucleotide polymorphism; WT, wild-type (allele)

*Bolded nucleotides indicate the SNP; underlined nucleotides indicate deliberately incorporated antepenultimate/penultimate mismatches to enhance allele specificity

     Figures

Figure 1. *In vivo* expression of *Pseudomonas aeruginosa* antimicrobial resistance loci in six cystic

fibrosis (CF) and five chronic obstructive pulmonary disease (COPD) sputa. Gene expression for each

sample at each locus was first normalised against *rpsL* (ΔC_T); relative expression was then

determined by comparing ΔC_T values against COPD participant SCHI0070 (i.e. $\Delta\Delta C_T$), who was not

receiving anti-pseudomonal antibiotics at the time of sputum collection. For SCHI0030, in which

longitudinal sputa over antibiotic treatment were obtained, only the Day 0 sputum was used in this

analysis to ensure independence of all observations. *, adjusted $p < 0.05$, **, adjusted $p < 0.01$. Error

bars=95% confidence interval.

Figure 2. Differential expression (relative fold change) of *Pseudomonas aeruginosa* antimicrobial

resistance loci in cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) sputa. Gene

expression for each locus was first normalised against *rpsL* (ΔC_T); relative expression was then

determined by comparing ΔC_T values against COPD participant SCHI0070 (i.e. $\Delta\Delta C_T$), who was not

receiving anti-pseudomonal antibiotics at the time of sputum collection. For participants receiving

anti-pseudomonal antibiotics, sputa are denoted by 'Day post-antibiotics' (D) (see Table 1 for

details). Error bars, standard deviation. †Participants receiving non-pseudomonal antibiotics at the

time of sputum collection.

References

1. Alanis AJ. 2005. Resistance to antibiotics: Are we in the post-antibiotic era? Archives of Medical Research 36:697-705.

2. Zhen X, Lundborg CS, Sun X, Hu X, Dong H. 2019. Economic burden of antibiotic resistance in ESKAPE organisms: a systematic review. Antimicrob Resist Infect Control 8:137.

3. Mulani MS, Kamble EE, Kumkar SN, Tawre MS, Pardesi KR. 2019. Emerging strategies to combat ESKAPE Pathogens in the era of antimicrobial resistance: A review. Front Microbiol 10:539-539.

4. Bassetti M, Vena A, Croxatto A, Righi E, Guery B. 2018. How to manage *Pseudomonas aeruginosa* infections. Drugs Context 7:1-18.

5. Botelho J, Grosso F, Peixe L. 2019. Antibiotic resistance in *Pseudomonas aeruginosa* - Mechanisms, epidemiology and evolution. Drug Resist Updat 44:26-47.

6. Breidenstein EB, de la Fuente-Nunez C, Hancock RE. 2011. *Pseudomonas aeruginosa*: All roads lead to resistance. Trends Microbiol 19:419-26.

7. Shallcross LJ, Howard SJ, Fowler T, Davies SC. 2015. Tackling the threat of antimicrobial resistance: From policy to sustainable action. Philos Trans R Soc Lond B Biol Sci 370:1-5.

8. O'Neill J. 2014. Antimicrobial resistance: Tackling a crisis for the health and wealth of nations. Accessed 12 August 2021.

9. Patel A. 2021. Tackling antimicrobial resistance in the shadow of COVID-19. mBio 12:1-4.

10. Laxminarayan R, Duse A, Wattal C, Zaidi AKM, Wertheim HFL, Sumpradit N, Vlieghe E, Hara GL, Gould IM, Goossens H, Greko C, So AD, Bigdeli M, Tomson G, Woodhouse W, Ombaka E, Peralta AQ, Qamar FN, Mir F, Kariuki S, Bhutta ZA, Coates A, Bergstrom R, Wright GD, Brown ED, Cars O. 2013. Antibiotic resistance - the need for global solutions. Lancet Infect Dis 13:1057-1098.

11. Su M, Satola SW, Read TD. 2019. Genome-based prediction of bacterial antibiotic resistance. J Clin Microbiol 57:1-15.

12. Rossen JWA, Friedrich AW, Moran-Gilad J. 2018. Practical issues in implementing whole-genome-sequencing in routine diagnostic microbiology. Clin Microbiol Infect 24:355-360.

13. Madden DE, McCarthy KL, Bell SC, Olagoke O, Baird T, Neill J, Ramsay KA, Kidd TJ, Stewart AG, Subedi S, Choong K, Fraser TA, Sarovich DS, Price EP. 2021. Rapid fluoroquinolone resistance detection in *Pseudomonas aeruginosa* using mismatch amplification mutation assay-based real-time PCR. *medRxiv*.

14. Richardot C, Plesiat P, Fournier D, Monlezun L, Broutin I, Llanes C. 2015. Carbapenem resistance in cystic fibrosis strains of *Pseudomonas aeruginosa* as a result of amino acid substitutions in porin OprD. Int J Antimicrob Agents 45:529-32.

15. Godfroid M, Dagan T, Merker M, Kohl TA, Diel R, Maurer FP, Niemann S, Kupczok A. 2020. Insertion and deletion evolution reflects antibiotics selection pressure in a *Mycobacterium tuberculosis* outbreak. PLoS Pathog 16:1-24.

16. Huang TW, Chen TL, Chen YT, Lauderdale TL, Liao TL, Lee YT, Chen CP, Liu YM, Lin AC, Chang YH, Wu KM, Kirby R, Lai JF, Tan MC, Siu LK, Chang CM, Fung CP, Tsai SF. 2013. Copy number change of the NDM-1 sequence in a multidrug-resistant *Klebsiella pneumoniae* clinical isolate. PLoS One 8:1-12.

17. Chalhoub H, Sáenz Y, Rodriguez-Villalobos H, Denis O, Kahl BC, Tulkens PM, Van Bambeke F. 2016. High-level resistance to meropenem in clinical isolates of *Pseudomonas aeruginosa* in the absence of carbapenemases: role of active efflux and porin alterations. Int J Antimicrob Agents 48:740-743.

18. Stewart AG, Price EP, Schabacker K, Birikmen M, Harris PNA, Choong K, Subedi S, Sarovich DS. 2021. Molecular epidemiology of third-generation cephalosporin-resistant *Enterobacteriaceae* in Southeast Queensland, Australia. Antimicrob Agents Chemother 65:1-13.

531   19.   Chantratita N, Rholl DA, Sim B, Wuthiekanun V, Limmathurotsakul D, Amornchai P,
532   Thanwisai A, Chua HH, Ooi WF, Holden MT, Day NP, Tan P, Schweizer HP, Peacock SJ. 2011.
533   Antimicrobial resistance to ceftazidime involving loss of penicillin-binding protein 3 in
534   *Burkholderia pseudomallei*. Proc Natl Acad Sci U S A 108:17165-70.

535   20.   Martin LW, Robson CL, Watts AM, Gray AR, Wainwright CE, Bell SC, Ramsay KA, Kidd TJ, Reid
536   DW, Brockway B, Lamont IL. 2018. Expression of *Pseudomonas aeruginosa* antibiotic
537   resistance genes varies greatly during infections in cystic fibrosis patients. Antimicrob Agents
538   Chemother 62:1-11.

539   21.   Wheatley R, Diaz Caballero J, Kapel N, de Winter FHR, Jangir P, Quinn A, del Barrio-Tofiño E,
540   López-Causapé C, Hedge J, Torrens G, Van der Schalk T, Xavier BB, Fernández-Cuenca F,
541   Arenzana A, Recanatini C, Timbermont L, Sifakis F, Ruzin A, Ali O, Lammens C, Goossens H,
542   Kluytmans J, Kumar-Singh S, Oliver A, Malhotra-Kumar S, MacLean C. 2021. Rapid evolution
543   and host immunity drive the rise and fall of carbapenem resistance during an acute
544   *Pseudomonas aeruginosa* infection. Nat Commun 12:1-12.

545   22.   Lee JY, Ko KS. 2012. OprD mutations and inactivation, expression of efflux pumps and AmpC,
546   and metallo-beta-lactamases in carbapenem-resistant *Pseudomonas aeruginosa* isolates
547   from South Korea. Int J Antimicrob Agents 40:168-72.

548   23.   Cabot G, Ocampo-Sosa AA, Tubau F, Macia MD, Rodriguez C, Moya B, Zamorano L, Suarez C,
549   Pena C, Martinez-Martinez L, Oliver A. 2011. Overexpression of *AmpC* and efflux pumps in
550   *Pseudomonas aeruginosa* isolates from bloodstream infections: prevalence and impact on
551   resistance in a Spanish multicenter study. Antimicrob Agents Chemother 55:1906-11.

552   24.   Webb JR, Price EP, Somprasong N, Schweizer HP, Baird RW, Currie BJ, Sarovich DS. 2018.
553   Development and validation of a triplex quantitative real-time PCR assay to detect efflux
554   pump-mediated antibiotic resistance in *Burkholderia pseudomallei*. Future Microbiol
555   12:1403-1418.

556   25.   Poole K. 2011. *Pseudomonas aeruginosa:* Resistance to the max. Front Microbiol 2:1-13.

557   26.   Juan C, Moya B, Perez JL, Oliver A. 2006. Stepwise upregulation of the *Pseudomonas*
558   *aeruginosa* chromosomal cephalosporinase conferring high-level beta-lactam resistance
559   involves three AmpD homologues. Antimicrob Agents Chemother 50:1780-7.

560   27.   Shu JC, Kuo AJ, Su LH, Liu TP, Lee MH, Su IN, Wu TL. 2017. Development of carbapenem
561   resistance in *Pseudomonas aeruginosa* is associated with *OprD* polymorphisms, particularly
562   the amino acid substitution at codon 170. J Antimicrob Chemother 72:2489-2495.

563   28.   Sherrard LJ, Wee BA, Duplancic C, Ramsay KA, Dave KA, Ballard E, Wainwright CE, Grimwood
564   K, Sidjabat HE, Whiley DM, Beatson SA, Kidd TJ, Bell SC. 2021. Emergence and impact of *oprD*
565   mutations in *Pseudomonas aeruginosa* strains in cystic fibrosis. J Cyst Fibros 21:1-9.

566   29.   Lee JK, Lee YS, Park YK, Kim BS. 2005. Alterations in the GyrA and GyrB subunits of
567   topoisomerase II and the ParC and ParE subunits of topoisomerase IV in ciprofloxacin-
568   resistant clinical isolates of *Pseudomonas aeruginosa*. Int J Antimicrob Agents 25:290-5.

569   30.   Poole K, Tetro K, Zhao Q, Neshat S, Heinrichs DE, Bianco N. 1996. Expression of the multidrug
570   resistance operon mexA-mexB-oprM in *Pseudomonas aeruginosa*: mexR encodes a regulator
571   of operon expression. Antimicrob Agents Chemother 40:2021-8.

572   31.   Chen W, Wang D, Zhou W, Sang H, Liu X, Ge Z, Zhang J, Lan L, Yang CG, Chen H. 2016.
573   Novobiocin binding to NalD induces the expression of the MexAB-OprM pump in
574   *Pseudomonas aeruginosa*. Mol Microbiol 100:749-58.

575   32.   Köhler T, Epp SF, Curty LK, Pechère JC. 1999. Characterization of MexT, the regulator of the
576   MexE-MexF-OprN multidrug efflux system of *Pseudomonas aeruginosa*. J Bacteriol
577   181:6300-5.

578   33.   Morita Y, Tomida J, Kawamura Y. 2012. MexXY multidrug efflux system of *Pseudomonas*
579   *aeruginosa*. Front Microbiol 3:1-13.

580   34.   Aghazadeh M, Hojabri Z, Mahdian R, Nahaei MR, Rahmati M, Hojabri T, Pirzadeh T, Pajand O.
581   2014. Role of efflux pumps: MexAB-OprM and MexXY(-OprA), AmpC cephalosporinase and

582   OprD porin in non-metallo-beta-lactamase producing *Pseudomonas aeruginosa* isolated
583   from cystic fibrosis and burn patients. Infect Genet Evol 24:187-92.

584   35.   Poole K, Gotoh N, Tsujimoto H, Zhao Q, Wada A, Yamasaki T, Neshat S, Yamagishi J, Li XZ,
585   Nishino T. 1996. Overexpression of the mexC-mexD-oprJ efflux operon in nfxB-type
586   multidrug-resistant strains of *Pseudomonas aeruginosa*. Mol Microbiol 21:713-24.

587   36.   Fraud S, Campigotto AJ, Chen Z, Poole K. 2008. MexCD-OprJ multidrug efflux system of
588   *Pseudomonas aeruginosa:* Involvement in chlorhexidine resistance and induction by
589   membrane-damaging agents dependent upon the AlgU stress response sigma factor.
590   Antimicrob Agents Chemother 52:4478-4482.

591   37.   Gotoh N, Tsujimoto H, Tsuda M, Okamoto K, Nomura A, Wada T, Nakahashi M, Nishino T.
592   1998. Characterization of the MexC-MexD-OprJ Multidrug Efflux System in mexA-mexB-
593   oprM Mutants of *Pseudomonas aeruginosa*. Antimicrob Agents Chemother 42:1938-1943.

594   38.   Oh H, Stenhoff J, Jalal S, Wretlind B. 2003. Role of efflux pumps and mutations in genes for
595   topoisomerases II and IV in fluoroquinolone-resistant *Pseudomonas aeruginosa* strains.
596   Microb Drug Resist 9:323-8.

597   39.   Islam S, Jalal S, Wretlind B. 2004. Expression of the MexXY efflux pump in amikacin-resistant
598   isolates of *Pseudomonas aeruginosa*. Clin Microbiol Infect 10:877-83.

599   40.   Webb KA, Olagoke O, Baird T, Neill J, Pham A, Wells TJ, Ramsay KA, Bell SC, Sarovich DS,
600   Price EP. 2021. Genomic diversity and antimicrobial resistance of *Prevotella* spp. isolated
601   from chronic lung disease airways. Microb Genom 8:000754.

602   41.   Nadkarni MA, Martin FE, Jacques NA, Hunter N. 2002. Determination of bacterial load by
603   real-time PCR using a broad-range (universal) probe and primers set. Microbiology (Reading)
604   148:257-266.

605   42.   De Lamballerie X, Zandotti C, Vignoli C, Bollet C, de Micco P. 1992. A one-step microbial DNA
606   extraction method using "Chelex 100" suitable for gene amplification. Res Microbiol
607   143:785-90.

608   43.   Anuj SN, Whiley DM, Kidd TJ, Bell SC, Wainwright CE, Nissen MD, Sloots TP. 2009.
609   Identification of *Pseudomonas aeruginosa* by a duplex real-time polymerase chain reaction
610   assay targeting the *ecfX* and the *gyrB* genes. Diagn Microbiol Infect Dis 63:127-131.

611   44.   Horcajada JP, Montero M, Oliver A, Sorlí L, Luque S, Gómez-Zorrilla S, Benito N, Grau S. 2019.
612   Epidemiology and treatment of multidrug-resistant and extensively drug-resistant
613   *Pseudomonas aeruginosa* infections. Clin Microbiol Rev 32:1-52.

614   45.   Masuda N, Sakagawa E, Ohya S, Gotoh N, Tsujimoto H, Nishino T. 2000. Substrate
615   specificities of MexAB-OprM, MexCD-OprJ, and MexXY-oprM efflux pumps in *Pseudomonas*
616   *aeruginosa*. Antimicrob Agents Chemother 44:3322-7.

617   46.   Buffet-Bataillon S, Tattevin P, Maillard J-Y, Bonnaure-Mallet M, Jolivet-Gougeon A. 2016.
618   Efflux pump induction by quaternary ammonium compounds and fluoroquinolone resistance
619   in bacteria. Future Microbiol 11:81-92.

620   47.   Fetar H, Gilmour C, Klinoski R, Daigle DM, Dean CR, Poole K. 2011. mexEF-oprN multidrug
621   efflux operon of *Pseudomonas aeruginosa:* Regulation by the MexT activator in response to
622   nitrosative stress and chloramphenicol. Antimicrob Agents Chemother 55:508-514.

623   48.   Dunne WM, Jr., Hardin DJ. 2005. Use of several inducer and substrate antibiotic
624   combinations in a disk approximation assay format to screen for AmpC induction in patient
625   isolates of *Pseudomonas aeruginosa*, *Enterobacter* spp., *Citrobacter* spp., and *Serratia* spp. J
626   of Clin Microbiol 43:5945-5949.

627   49.   Oliver A, Baquero F, Blázquez J. 2002. The mismatch repair system (mutS, mutL and uvrD
628   genes) in *Pseudomonas aeruginosa*: molecular characterization of naturally occurring
629   mutants. Mol Microbiol 43:1641-50.

630   50.   van Belkum A, Soriaga LB, LaFave MC, Akella S, Veyrieras J-B, Barbu EM, Shortridge D, Blanc
631   B, Hannum G, Zambardi G, Miller K, Enright MC, Mugnier N, Brami D, Schicklin S, Felderman
632   M, Schwartz AS, Richardson TH, Peterson TC, Hubby B, Cady KC. 2015. Phylogenetic

distribution of CRISPR-Cas systems in antibiotic-resistant *Pseudomonas aeruginosa*. mBio
6:1-13.

51. Cabot G, López-Causapé C, Ocampo-Sosa AA, Sommer LM, Domínguez MÁ, Zamorano L,
Juan C, Tubau F, Rodríguez C, Moyà B, Peña C, Martínez-Martínez L, Plesiat P, Oliver A. 2016.
Deciphering the resistome of the widespread *Pseudomonas aeruginosa* sequence type 175
international high-risk clone through whole-genome sequencing. Antimicrob Agents
Chemother 60:7415-7423.

52. Kos VN, Déraspe M, McLaughlin RE, Whiteaker JD, Roy PH, Alm RA, Corbeil J, Gardner H.
2015. The resistome of *Pseudomonas aeruginosa* in relationship to phenotypic susceptibility.
Antimicrob Agents Chemother 59:427-436.

53. Del Barrio-Tofiño E, López-Causapé C, Cabot G, Rivera A, Benito N, Segura C, Montero MM,
Sorlí L, Tubau F, Gómez-Zorrilla S, Tormo N, Durá-Navarro R, Viedma E, Resino-Foz E,
Fernández-Martínez M, González-Rico C, Alejo-Cancho I, Martínez JA, Labayru-Echverria C,
Dueñas C, Ayestarán I, Zamorano L, Martinez-Martinez L, Horcajada JP, Oliver A. 2017.
Genomics and susceptibility profiles of extensively drug-resistant *Pseudomonas aeruginosa*
isolates from Spain. Antimicrob Agents Chemother 61:1-13.

54. Sherrard LJ, Tai AS, Wee BA, Ramsay KA, Kidd TJ, Ben Zakour NL, Whiley DM, Beatson SA,
Bell SC. 2017. Within-host whole genome analysis of an antibiotic resistant *Pseudomonas*
aeruginosa strain sub-type in cystic fibrosis. PLoS ONE 12:1-15.

55. Fraser TA, Bell MG, Harris PNA, Bell SC, Bergh H, Nguyen T-K, Kidd TJ, Nimmo GR, Sarovich
DS, Price EP. 2019. Quantitative real-time PCR assay for the rapid identification of the
intrinsically multidrug-resistant bacterial pathogen *Stenotrophomonas maltophilia*. Microb
Genom 5:2-11.

56. Price EP, Dale JL, Cook JM, Sarovich DS, Seymour ML, Ginther JL, Kaufman EL, Beckstrom-
Sternberg SM, Mayo M, Kaestli M, Glass MB, Gee JE, Wuthiekanun V, Warner JM, Baker A,
Foster JT, Tan P, Tuanyok A, Limmathurotsakul D, Peacock SJ, Currie BJ, Wagner DM, Keim P,
Pearson T. 2012. Development and validation of *Burkholderia pseudomallei*-specific real-
time PCR assays for clinical, environmental or forensic detection applications. PLoS One 7:1-
9.

57. Araujo P. 2009. Key aspects of analytical method validation and linearity evaluation. J
Chromatogr B Analyt Technol Biomed Life Sci 877:2224-34.

58. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time
quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402-8.

59. Madden DE, Webb JR, Steinig EJ, Currie BJ, Price EP, Sarovich DS. 2021. Taking the next-gen
step: Comprehensive antimicrobial resistance detection from *Burkholderia pseudomallei*.
EBioMedicine 63:103152.

60. Juan C, Macia MD, Gutierrez O, Vidal C, Perez JL, Oliver A. 2005. Molecular mechanisms of β-
lactam resistance mediated by AmpC hyperproduction in *Pseudomonas aeruginosa* clinical
strains. Antimicrob Agents Chemother 49:4733-8.

61. Tomás M, Doumith M, Warner M, Turton JF, Beceiro A, Bou G, Livermore DM, Woodford N.
2010. Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in *Pseudomonas*
aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother 54:2219-
2224.

62. Purssell A, Poole K. 2013. Functional characterization of the NfxB repressor of the *mexCD-*
oprJ multidrug efflux operon of *Pseudomonas aeruginosa*. Microbiology (Reading) 159:2058-
2073.

63. Livermore DM. 1995. Beta-Lactamases in laboratory and clinical resistance. Clin Microbiol
Rev 8:557-84.

64. Rehman A, Jeukens J, Levesque RC, Lamont IL. 2021. Gene-gene interactions dictate
ciprofloxacin resistance in *Pseudomonas aeruginosa* and facilitate prediction of resistance
phenotype from genome sequence data. Antimicrob Agents Chemother 65:1-15.

65. Clark ST, Sinha U, Zhang Y, Wang PW, Donaldson SL, Coburn B, Waters VJ, Yau YCW, Tullis
DE, Guttman DS, Hwang DM. 2019. Penicillin-binding protein 3 is a common adaptive target
among *Pseudomonas aeruginosa* isolates from adult cystic fibrosis patients treated with β-
lactams. Int J Antimicrob Agents 53:620-628.
66. Bolard A, Plésiat P, Jeannot K. 2018. Mutations in gene fusA1 as a novel mechanism of
aminoglycoside resistance in clinical strains of *Pseudomonas aeruginosa*. Antimicrob Agents
Chemother 62:1-10.
67. Köhler T, Michéa-Hamzehpour M, Henze U, Gotoh N, Curty LK, Pechère JC. 1997.
Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of
Pseudomonas aeruginosa. Mol Microbiol 23:345-54.
68. Zamorano L, Moya B, Juan C, Oliver A. 2010. Differential beta-lactam resistance response
driven by *ampD* or *dacB* (PBP4) inactivation in genetically diverse *Pseudomonas aeruginosa*
strains. J Antimicrob Chemother 65:1540-2.
69. Winstanley C, O'Brien S, Brockhurst MA. 2016. *Pseudomonas aeruginosa* evolutionary
adaptation and diversification in cystic fibrosis chronic lung infections. Trends Microbiol
24:327-337.
70. Valderrey AD, Pozuelo MJ, Jiménez PA, Maciá MD, Oliver A, Rotger R. 2010. Chronic
colonization by *Pseudomonas aeruginosa* of patients with obstructive lung diseases: cystic
fibrosis, bronchiectasis, and chronic obstructive pulmonary disease. Diagn Microbiol Infect
Dis 68:20-7.
71. Lee M, Hesek D, Blázquez B, Lastochkin E, Boggess B, Fisher JF, Mobashery S. 2015. Catalytic
spectrum of the penicillin-binding protein 4 of *Pseudomonas aeruginosa*, a nexus for the
induction of β-lactam antibiotic resistance. J Am Chem Soc 137:190-200.
72. Van den Bossche S, De Broe E, Coenye T, Van Braeckel E, Crabbé A. 2021. The cystic fibrosis
lung microenvironment alters antibiotic activity: Causes and effects. Eur Respir Rev 30:1-16.
73. Vettoretti L, Plesiat P, Muller C, El Garch F, Phan G, Attree I, Ducruix A, Llanes C. 2009. Efflux
unbalance in *Pseudomonas aeruginosa* isolates from cystic fibrosis patients. Antimicrob
Agents Chemother 53:1987-97.
74. Goodman AL, Kulasekara B, Rietsch A, Boyd D, Smith RS, Lory S. 2004. A signaling network
reciprocally regulates genes associated with acute infection and chronic persistence in
Pseudomonas aeruginosa. Dev Cell 7:745-54.
75. Werner E, Roe F, Bugnicourt A, Franklin MJ, Heydorn A, Molin S, Pitts B, Stewart PS. 2004.
Stratified growth in *Pseudomonas aeruginosa* biofilms. Appl Environ Microbiol 70:6188-96.
76. Murphy TF. 2008. The many faces of *Pseudomonas aeruginosa* in chronic obstructive
pulmonary disease. Clin Infect Dis 47:1534-1536.
77. Quale J, Bratu S, Gupta J, Landman D. 2006. Interplay of efflux system, *ampC*, and *oprD*
expression in carbapenem resistance of *Pseudomonas aeruginosa* clinical isolates.
Antimicrob Agents Chemother 50:1633-1641.
78. Pai H, Kim J, Kim J, Lee JH, Choe KW, Gotoh N. 2001. Carbapenem resistance mechanisms in
Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 45:480-4.
79. Fung C, Naughton S, Turnbull L, Tingpej P, Rose B, Arthur J, Hu H, Harmer C, Harbour C,
Hassett DJ, Whitchurch CB, Manos J. 2010. Gene expression of *Pseudomonas aeruginosa* in a
mucin-containing synthetic growth medium mimicking cystic fibrosis lung sputum. J Med
Microbiol 59:1089-1100.
80. Hill D, Rose B, Pajkos A, Robinson M, Bye P, Bell S, Elkins M, Thompson B, MacLeod C, Aaron
SD, Harbour C. 2005. Antibiotic susceptibilies of *Pseudomonas aeruginosa* isolates derived
from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions. J of Clin
Microbiol 43:5085-5090.
81. Kirchner S, Fothergill JL, Wright EA, James CE, Mowat E, Winstanley C. 2012. Use of artificial
sputum medium to test antibiotic efficacy against *Pseudomonas aeruginos*a in conditions
more relevant to the cystic fibrosis lung. J Vis Exp 64:1-7.

735